.webp)
Quick Dispatch:
Your summit study tirzepatide In pts wiht HFpEF and obesity, tirzepatide (Mounjaro®) significantly reduces HF hospitalization, diuretic intensification, or CV death by 38% vs placebo in SUMMIT trial https://t.co/8ZHm4gySiL orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your summit study tirzepatide In pts wiht HFpEF and obesity, tirzepatide (Mounjaro®) significantly reduces HF hospitalization, diuretic intensification, or CV death by 38% vs placebo in SUMMIT trial https://t.co/8ZHm4gySiL ships.
Need Help?
Questions about summit study tirzepatide In pts wiht HFpEF and obesity, tirzepatide (Mounjaro®) significantly reduces HF hospitalization, diuretic intensification, or CV death by 38% vs placebo in SUMMIT trial https://t.co/8ZHm4gySiL, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for summit study tirzepatide In pts wiht HFpEF and obesity, tirzepatide (Mounjaro®) significantly reduces HF hospitalization, diuretic intensification, or CV death by 38% vs placebo in SUMMIT trial https://t.co/8ZHm4gySiL in your area.
Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial
24.92
Another "Positive" Heart Failure Trial that Falls Short
28.12
Reaching the SUMMIT? Benefits and potential risks associated with the use of tirzepatide in heart failure with preserved ejection fraction
20.06
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
24.50
Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial
22.64
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
20.89
Impact of Obesity Severity on the Effects of Tirzepatide in HFpEF: The SUMMIT Trial
29.10
